Ranexa
Product indicated to support angina pectoris management and designed to relieve symptoms by modifying cardiac ionic currents.
- Category
- Heart & Blood Pressure
- Active ingredient
- Ranolazine
- Supply
- Pharmacy
- Route
- Oral use
- Form
- Prolonged-release tablet
- Strengths
- 500 · 1000mg
Ranexa details
- Condition
- Stable Angina Pectoris
- Therapeutic class
- Anti-anginal Drug
- Pharmacological class
- Late Sodium Current Inhibitor
- Minor side effects
- dizziness; constipation; nausea; headache
- Moderate side effects
- fatigue; asthenia; blurred vision
- Dosage forms
- Prolonged-release tablet
- Administration route
- Oral use
- Supply category
- Pharmacist only, dispensed without a prescription
- Manufacturer
- Menarini
- Onset Time
- 1–2 days
- Duration
- 24 hours
- Drug interactions
- ketoconazole; verapamil; diltiazem; simvastatin
- Age restrictions
- Not recommended for those under 18 years.
- Pregnancy and breastfeeding
- Pregnancy: Not recommended. Breastfeeding: Not recommended.
Contraindications
hypersensitivity; severe renal impairment; severe hepatic impairment; concurrent use of potent CYP3A4 inhibitors
Precautions and warnings
monitor for arrhythmias; use caution in elderly patients; regular electrocardiogram monitoring required
Serious side effects
qt prolongation, requires immediate medical attention; ventricular arrhythmias, requires immediate medical attention; syncope, requires immediate medical attention
Patient summary
Product indicated to support angina pectoris management and designed to relieve symptoms by modifying cardiac ionic currents.
Mechanism of action
This medicine inhibits the late sodium current in heart muscle cells, which prevents sodium and calcium overload, improving cardiac relaxation and blood flow efficiency.
Storage instructions
Store at room temperature, keep in original packaging, and protect from moisture.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Ranexa
Ranexa contains Ranolazine, a recognised treatment for chronic, stable angina pectoris. Manufactured by Menarini, this medication is supplied as a tablet in strengths of 500mg and 1000mg. It is frequently chosen by patients seeking a reliable method to manage heart-related chest pain symptoms.
Buying Ranexa online
Ranexa is registered across 14 markets, including Japan, the UAE and Singapore, with availability extending to Hong Kong, Thailand and Malaysia. As many patients across Asia live far from a well stocked physical pharmacy or seek cost-effective access to consistent supplies, this option is one of the most ordered for the condition across the region. A reliable supply chain ensures that consistent access is maintained regardless of current location.